• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Journal of clinical neuromuscular disease

    Journal of clinical neuromuscular disease

    JournalISSN 1522-0443eISSN 1537-1611

    年发文量

    研究主题

    论文(1034)

    排序
    1Proteomic and Functional Signatures of Phenoconversion in Presymptomatic Amyotrophic Lateral Sclerosis.
    Steven Lehrer,Peter H Rheinstein

    BACKGROUND:Amyotrophic lateral sclerosis (ALS) likely has a prolonged presymptomatic phase. Identifying blood biomarkers that predict phenoconversion is critical for early intervention. METHODS:We analyzed baseline serum proteomics in 270 UK Biobank participants who later developed ALS. A prespecified 19-protein panel was evaluated in relation to time-to-diagnosis. C9orf72 risk was proxied using rs10757668 genotype. RESULTS:Neurofilament light rose sharply in the 2-3 years preceding diagnosis (r = -0.37, P < 0.001). Muscle-stress markers, including EDA2R and MYL3, increased earlier, up to 4-6 years before onset. Higher EDA2R levels were associated with reduced grip strength at baseline. A combined 19-protein panel plus genotype predicted phenoconversion within 3 years with an area under the receiver operating characteristic curve of 0.77, outperforming neurofilament light alone. CONCLUSIONS:ALS exhibits a measurable molecular prodrome detectable in blood years before diagnosis. Integrated proteomic and genetic profiling may support early identification and trial enrichment strategies.

    2026
    引用
    AI阅读
    加入学术空间
    2Acute Pharyngeal-Cervical-Brachial Weakness Associated with Urinary Retention and Anti-GD1a Antibodies: A Case Report.
    Fabio Giuseppe Masuccio, Greta Negro,Carlo Civardi,Claudio Solaro
    2026
    引用
    AI阅读
    加入学术空间
    3Ultrasound-Guided Perineural Corticosteroid Injection for Bell Palsy in a Patient Recovering from Diabetic Ketoacidosis: an Alternative when Systemic Corticosteroids Are Contraindicated.
    Hilmi Berkan Abacıoğlu,Berkay Yalçınkaya, Ahmet Furkan Çolak,Murat Kara
    2026
    引用
    AI阅读
    加入学术空间
    4Chronic Inflammatory Demyelinating Polyneuropathy: Update on Diagnosis and Treatment.
    Jin Jun Luo, Xiaohong Si

    ABSTRACT:Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy characterized by progressive or relapsing weakness and sensory loss because of demyelination of peripheral nerves. CIDP has a higher prevalence in men and older adults. Immunopathogenesis involves both cellular and humoral mechanisms, including autoreactive T cells and macrophage-mediated demyelination. Typical CIDP presents with symmetric sensorimotor deficits, whereas atypical variants such as distal acquired demyelinating symmetric neuropathy, Lewis-Sumner syndrome, and motor- or sensory-predominant forms pose diagnostic challenges. Corticosteroids, intravenous immunoglobulin, and plasma exchange remain first-line treatments, although antibody-mediated subtypes often respond better to B-cell-directed therapy. The newly FDA-approved FcRn antagonist, efgartigimod alfa, provides a targeted option for adults with refractory CIDP. Accurate recognition of atypical and antibody-associated forms is essential for optimizing individualized management and improving outcomes.

    2026
    引用
    AI阅读
    加入学术空间
    5Fatal Myocarditis Relapse in a Patient with Myasthenia Gravis Treated with Efgartigimod Alfa: A Case Report.
    Tal Friedman Korn, Omri Zveik-Lavi, Dana Ekstein,Adi Vaknin-Dembinsky, Ronen Durst, Batla Falah,Marc Gotkine

    ABSTRACT:Myasthenia gravis (MG) is an autoimmune neuromuscular disorder primarily caused by autoantibodies against acetylcholine receptors (AChR), leading to muscle weakness. In 2021, efgartigimod was FDA-approved as the first neonatal Fc receptor (FcRn) blocker for generalized MG, reducing pathogenic IgG autoantibodies and improving symptoms. We present a 39-year-old woman with AChR-positive generalized MG and a history of resolved inflammatory myocarditis. Owing to persistent weakness despite intravenous immunoglobulin, she transitioned to efgartigimod. Efgartigimod induced significant neuromuscular improvement, reducing her myasthenia gravis activities of daily living (MG-ADL) score from 9 to 4. However, 3 months later, she developed fatal fulminant heart failure (LVEF 20%-25%) without concurrent skeletal muscle weakness. Despite emergency intervention with veno-arterial extracorporeal membrane oxygenation, the patient died after anoxic brain injury. Although efgartigimod effectively reduces pathogenic IgG, it may not adequately suppress cellular or cytokine-mediated inflammation driving MG-associated myocarditis. Clinicians should exercise caution and maintain cardiac monitoring when prescribing FcRn blockers to patients with a history of myocardial involvement.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1034 篇论文

    高被引作者

    作者引用发文
    Milton Alter8371
    William R Kennedy8371
    Gil I Wolfe55515
    Susan T Iannaccone4187
    Richard J. Barohn36510
    David Lacomis30436
    Thomas H. Brannagan25517
    Linda S Hynan2272
    Christine A. Limbers2121
    James Varni2121

    高产作者

    作者引用发文
    David Lacomis30436
    Bashar Katirji17317
    Thomas H. Brannagan25517
    Gil I Wolfe55515
    Bertorini Tulio9415
    Nizar Souayah17613
    Mark B. Bromberg12613
    Rahman Pourmand11111
    Zachary Simmons12511
    P. James B. Dyck15710

    相关期刊

    Ceskoslovenska neurologie a neurochirurgie
    Rinsho shinkeigaku = Clinical neurology
    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
    Case reports in neurology
    Case reports in neurological medicine
    Neurology And Clinical Neuroscience
    Practical Neurology
    eNeurologicalSci
    Clinical And Experimental Neuroimmunology
    EMC - Neurologia